Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
11000 participants
INTERVENTIONAL
2024-12-09
2036-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main objective of this study is to determine the incidence of pathologies occurring during travel outside the metropolitan territory.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Vaccination Coverage and Determinants of Success of the COVID-19 Vaccination Program Among Populations in Very Precarious Situations
NCT05075941
TOURIST 2: Tracking Of Urgent Risks In Swiss Travelers
NCT03262337
Investigation of Endemic and Emerging Diseases in Populations of Homeless Households in Marseille.
NCT02819128
Rural South and Southeast Asia Household Health Survey
NCT05389540
A Study of Overcoming Social Determinants of Health
NCT05773313
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main objective of this study is to determine the incidence of pathologies occurring during travel outside the metropolitan territory.
Furthermore, two key aspects from a Public Health perspective are associated with travel and the globalization of exchanges: the acquisition of emerging pathogens or pathogens with antimicrobial resistance of concern.
To study these two aspects, the EOP study includes two sub-studies called EOP-Arbo and EOP-AMR.
* EOP-Arbo : The objective of this sub-study is to determine the risk of contracting an arboviral disease during travel, as well as the factors that may favor infection. For this, blood samples will be collected.
* EOP-AMR : The objective of this sub-study is to determine the risk of contracting an antibiotic-resistant bacteria during the trip. For this, faecal samples will be collected.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Adults planning to travel outside metropolitan France.
Human biological samples :
* Blood sample
* fecal sample
Blood sample collection
16 mL at inclusion 16 mL at 1 month after return from travel
Fecal sample collection
1 sample at inclusion
1 sample at day 1, day 7, day 14, day 21, 1 month and 2 month after return from travel
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sample collection
16 mL at inclusion 16 mL at 1 month after return from travel
Fecal sample collection
1 sample at inclusion
1 sample at day 1, day 7, day 14, day 21, 1 month and 2 month after return from travel
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Major subject (age ≥ 18)
* Owns a smartphone compatible with electronic data collection
* Preparing to travel outside mainland France
* Affiliated with or covered by Social Security or private insurance
* Willing to participate in the EOP study
2. For the EOP-Arbo Sub-study :
\- Subject who has consented to participate in the EOP\_Arbo study.
3. For the EOP-AMR Sub-study :
* Subject who has consented to participate in the EOP\_AMR study.
Exclusion Criteria
* Travel duration ≤ 3 days
* Travel duration \> 12 months
* Person traveling as part of an expatriation without planned movement outside the settlement in the destination country
* Person under legal protection or unable to express consent for participation
2. For the EOP-Arbo Sub-study :
\- Individuals deemed clinically and/or biologically unfit by the investigator to undergo the blood samples required for the study.
3. For the EOP-AMR Sub-study :
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Pasteur
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fabien TAIEB, MD
Role: PRINCIPAL_INVESTIGATOR
Medical Center of Institut Pasteur
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Center of Institut Pasteur
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-A02574-41
Identifier Type: OTHER
Identifier Source: secondary_id
2022-069
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.